Article
Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.
Heart (British Cardiac Society) - 1 Apr 2011
Park Kyung Woo, Park Jin Joo, Lee Seung-Pyo, Oh Il-Young, Suh Jung-Won, Yang Han-Mo, Lee Hae-Young, Kang Hyun-Jae, Cho Young-Suk, Koo Bon-Kwon, Youn Tae-Jin, Chae In-Ho, Choi Dong-Ju, Oh Byung-Hee, Park Young-Bae, Kim Hyo-Soo
Abstract excerpt
OBJECTIVE: To evaluate whether the addition of cilostazol to dual antiplatelet therapy (DAT, aspirin plus clopidogrel) can attenuate clopidogrel on-treatment platelet reactivity (OPR) in patients with the CYP2C19 loss-of-function (LOF) allele. METHODS: In the CILON-T randomised trial, patients were randomly assigned to either DAT or triple antiplatelet therapy (TAT, DAT plus cilostazol). Genotyping of cytochrome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.